Tags

Type your tag names separated by a space and hit enter

Effects of CDP-choline and the combination of CDP-choline and galantamine differ in an animal model of schizophrenia: development of a selective alpha7 nicotinic acetylcholine receptor agonist strategy.
Eur Neuropsychopharmacol. 2008 Feb; 18(2):147-51.EN

Abstract

The regionally selective reduction of expression of the alpha7 nicotinic acetylcholine receptor (alpha7 nAChR) in schizophrenia underlies impaired sensory inhibition, a possible endophenotype of the disorder. This ligand-gated ion channel receptor has been proposed as a pharmacotherapeutic target in schizophrenia. The current study examined the effect of CDP-choline alone and the combination of CDP-choline and galantamine, administered acutely and once-daily for five consecutive days, in an animal model of NMDA receptor hypofunction that is relevant to schizophrenia. The results support the allosteric modulatory influence of galantamine on CDP-choline; however, individual doses of CDP-choline and galantamine must be carefully titrated in order to achieve optimal levels of alpha7 nAChR "agonism" that may be necessary for the desired therapeutic effect.

Authors+Show Affiliations

Mental Health Service Line (116A), Department of Veterans Affairs Medical Center, 50 Irving Street, NW, Washington, DC 20422, United States. Stephen.Deutsch@med.va.govNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, U.S. Gov't, Non-P.H.S.

Language

eng

PubMed ID

17656074

Citation

Deutsch, Stephen I., et al. "Effects of CDP-choline and the Combination of CDP-choline and Galantamine Differ in an Animal Model of Schizophrenia: Development of a Selective Alpha7 Nicotinic Acetylcholine Receptor Agonist Strategy." European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology, vol. 18, no. 2, 2008, pp. 147-51.
Deutsch SI, Rosse RB, Schwartz BL, et al. Effects of CDP-choline and the combination of CDP-choline and galantamine differ in an animal model of schizophrenia: development of a selective alpha7 nicotinic acetylcholine receptor agonist strategy. Eur Neuropsychopharmacol. 2008;18(2):147-51.
Deutsch, S. I., Rosse, R. B., Schwartz, B. L., Schooler, N. R., Gaskins, B. L., Long, K. D., & Mastropaolo, J. (2008). Effects of CDP-choline and the combination of CDP-choline and galantamine differ in an animal model of schizophrenia: development of a selective alpha7 nicotinic acetylcholine receptor agonist strategy. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology, 18(2), 147-51.
Deutsch SI, et al. Effects of CDP-choline and the Combination of CDP-choline and Galantamine Differ in an Animal Model of Schizophrenia: Development of a Selective Alpha7 Nicotinic Acetylcholine Receptor Agonist Strategy. Eur Neuropsychopharmacol. 2008;18(2):147-51. PubMed PMID: 17656074.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of CDP-choline and the combination of CDP-choline and galantamine differ in an animal model of schizophrenia: development of a selective alpha7 nicotinic acetylcholine receptor agonist strategy. AU - Deutsch,Stephen I, AU - Rosse,Richard B, AU - Schwartz,Barbara L, AU - Schooler,Nina R, AU - Gaskins,Brooke L, AU - Long,Katrice D, AU - Mastropaolo,John, Y1 - 2007/07/26/ PY - 2007/04/16/received PY - 2007/05/30/accepted PY - 2007/7/28/pubmed PY - 2008/4/19/medline PY - 2007/7/28/entrez SP - 147 EP - 51 JF - European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology JO - Eur Neuropsychopharmacol VL - 18 IS - 2 N2 - The regionally selective reduction of expression of the alpha7 nicotinic acetylcholine receptor (alpha7 nAChR) in schizophrenia underlies impaired sensory inhibition, a possible endophenotype of the disorder. This ligand-gated ion channel receptor has been proposed as a pharmacotherapeutic target in schizophrenia. The current study examined the effect of CDP-choline alone and the combination of CDP-choline and galantamine, administered acutely and once-daily for five consecutive days, in an animal model of NMDA receptor hypofunction that is relevant to schizophrenia. The results support the allosteric modulatory influence of galantamine on CDP-choline; however, individual doses of CDP-choline and galantamine must be carefully titrated in order to achieve optimal levels of alpha7 nAChR "agonism" that may be necessary for the desired therapeutic effect. SN - 0924-977X UR - https://www.unboundmedicine.com/medline/citation/17656074/Effects_of_CDP_choline_and_the_combination_of_CDP_choline_and_galantamine_differ_in_an_animal_model_of_schizophrenia:_development_of_a_selective_alpha7_nicotinic_acetylcholine_receptor_agonist_strategy_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0924-977X(07)00123-X DB - PRIME DP - Unbound Medicine ER -